Photocure ASA - Annual Overview
Issuers of listed transferable securities on the Oslo Stock Exchange are, according to the Securities Trading Act section §5-11 required to provide Oslo Stock Exchange with a document listing all relevant information they have made available to the public over the preceding 12 months in compliance with their legal obligations.
Attached is an overview of all information made available to the public from Photocure from 2 April 2009 until 13 April 2010.
All the information is available on the company's website, www.photocure.com
For more information, please contact:
CFO Christian Fekete
Tel. 22 06 22 10
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
Photocure's commercial activities includes own marketing and sales in selected markets as well as out-licensing on a regional or global basis prior to phase III.
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the company has developed a proprietary light source, which is used in combination with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM) platform.
Photocure®, the Photocure logo and Hexvix® are registered trademarks of Photocure ASA.